Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIJEX vs DELTALIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.
Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.
Management of secondary hyperparathyroidism in patients with chronic kidney disease stage 3, 4, and 5 on dialysis,Hypocalcemia in patients with hypoparathyroidism,Hypocalcemia in renal osteodystrophy,Off-label: treatment of hypocalcemia due to pseudohypoparathyroidism or vitamin D-dependent rickets
Adjunctive treatment of hypocalcemia in hypoparathyroidism,Treatment of refractory rickets,Dietary supplementation for vitamin D deficiency
Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.
0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.
Terminal elimination half-life ranges from 5 to 10 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 20 hours or more.
Terminal elimination half-life ranges from 24 to 36 hours in adults with normal renal function; may be prolonged (up to 72 hours) in renal impairment.
Primarily hepatic via 24-hydroxylation; also undergoes further oxidation and conjugation. Not significantly metabolized by CYP450 enzymes.
Hepatic hydroxylation to active metabolites (e.g., calcifediol, calcitriol); undergoes enterohepatic recycling.
Primarily hepatic (biliary-fecal) elimination; approximately 2-4% excreted unchanged in urine. Small amount undergoes enterohepatic recirculation.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose; biliary/fecal elimination accounts for 30-40%, primarily as metabolites.
Approximately 99.9% bound to vitamin D-binding protein (DBP) and albumin.
~95% bound primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution (Vd) is approximately 0.25 L/kg (range 0.2-0.3 L/kg). This low Vd indicates distribution mainly to extracellular fluid and tissues.
Apparent volume of distribution (Vd) is 0.5-1.0 L/kg, indicating moderate tissue distribution.
Oral bioavailability is approximately 60-70% when administered as the injectable formulation orally; however, for IV administration, bioavailability is 100%.
Oral: 80-90%; Intramuscular: 90-100% (assumes complete absorption); Intravenous: 100%.
For GFR < 30 m L/min: reduce initial dose to 0.25 mcg oral or 0.5 mcg IV three times weekly. No adjustment for GFR > 30 m L/min.
No adjustment required for GFR ≥30 m L/min; use with caution and reduce dose by 50% for GFR <30 m L/min; contraindicated in dialysis.
No specific recommendations for Child-Pugh classes; caution in severe hepatic impairment due to risk of accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Intravenous: 0.01-0.05 mcg/kg three times weekly; titrate based on calcium and PTH levels. Oral: 0.015-0.025 mcg/kg once daily.
0.01 mg/kg orally once daily, not to exceed 0.5 mg daily; adjust based on response.
Start at low end of dosing range (0.25 mcg oral or 0.25-0.5 mcg IV three times weekly); monitor calcium and phosphate closely due to increased sensitivity.
Initiate at 0.25 mg orally once daily; titrate slowly due to increased sensitivity and risk of hypotension.
None
None.
Hypercalcemia, hypercalciuria, hyperphosphatemia; aluminum hydroxide use may increase aluminum absorption; avoid vitamin D supplementation; monitor serum calcium and phosphate levels regularly; caution in patients with coronary artery disease (calcium load).
May cause hypercalcemia; monitor serum calcium and phosphate levels regularly. Use with caution in patients with renal impairment, hyperphosphatemia, or sarcoidosis. Avoid use in patients with evidence of vitamin D toxicity.
Hypercalcemia, vitamin D toxicity, known hypersensitivity to calcitriol or any component of the formulation.
Hypercalcemia, hypervitaminosis D, malabsorption syndrome, and known hypersensitivity to vitamin D or any component of the formulation.
Avoid excessive dietary calcium (dairy products, fortified foods) during treatment. Do not take calcium-containing antacids or supplements. Maintain adequate fluid intake to prevent hypercalcemia.
No specific food interactions; however, dietary calcium intake should be consistent. High magnesium foods may affect absorption? No. Avoid excessive intake of calcium-rich foods if hypercalcemia risk.
Calcitriol (CALCIJEX) is a Vitamin D analog. Based on animal studies, there is evidence of teratogenicity at high doses (skeletal abnormalities, reduced fetal weight). Human data are limited. Pregnancy Category C. First trimester: Theoretical risk of teratogenicity if hypercalcemia occurs; avoid excessive doses. Second and third trimesters: Risk of fetal hypercalcemia and suppression of parathyroid function if maternal hypercalcemia develops; use only if clearly needed and monitor maternal calcium levels.
FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is highest in the first trimester. Avoid use during pregnancy unless benefit outweighs risk.
Calcitriol is excreted into human breast milk but in low amounts. No adverse effects reported in nursing infants. The M/P ratio is not established. Caution is advised due to risk of hypercalcemia in the infant; monitor infant serum calcium if maternal use is necessary.
Deltalin is excreted in human milk. The M/P ratio is unknown. Caution is advised; consider the risk of hypercalcemia in the breastfed infant. Monitoring of infant serum calcium is recommended if used.
Dosing adjustments may be required due to altered calcium metabolism in pregnancy. Increase in glomerular filtration rate (GFR) and expanded plasma volume may increase clearance, potentially requiring higher doses. However, maintain normocalcemia; monitor serum calcium and adjust dose accordingly. Starting dose typically unchanged but may need titration based on calcium levels.
Dose adjustments may be necessary due to increased vitamin D metabolism and clearance during pregnancy. Monitor serum calcium and 25-hydroxyvitamin D to guide dosing. Initial doses may require increase, but avoid supratherapeutic levels.
Monitor serum calcium and phosphate levels closely; hypercalcemia risk is highest with concurrent thiazide use or high calcium intake. Adjust dose based on PTH levels in CKD patients. Use with caution in digitalis-treated patients due to additive positive inotropic effect.
Deltalin (ergocalciferol) is a vitamin D2 supplement used for deficiency and prophylaxis. Monitor serum calcium and phosphate levels during therapy. Use caution in patients with hypercalcemia, hypercalciuria, or renal impairment. Deltalin can increase digoxin toxicity risk via hypercalcemia. For rickets, radiographic healing confirms efficacy.
Take this medication exactly as prescribed; do not change dose or frequency without consulting your doctor.,Alert your doctor if you experience symptoms of high calcium: nausea, vomiting, constipation, muscle weakness, or confusion.,Avoid excessive intake of calcium-rich foods, supplements, or antacids during treatment.,You may need regular blood tests to monitor calcium, phosphate, and parathyroid hormone levels.,Inform all healthcare providers that you are taking Calcijex.
Take exactly as prescribed; do not double dose if missed.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, or confusion.,Avoid taking with other vitamin D supplements unless directed by healthcare provider.,Inform healthcare provider of all medications, especially digoxin, thiazide diuretics, and antacids.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIJEX vs DELTALIN, answered by our medical review team.
CALCIJEX is a Vitamin D Analog that works by Calcitriol, the active form of vitamin D, binds to the vitamin D receptor (VDR) in target tissues, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and stimulating bone resorption. It also suppresses parathyroid hormone (PTH) synthesis and secretion via negative feedback.. DELTALIN is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIJEX and DELTALIN depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIJEX is: Intravenous: 0.5 mcg three times per week during dialysis; may be increased by 0.25-0.5 mcg at 2-4 week intervals. Oral: 0.25 mcg daily; may be increased to 0.5 mcg daily.. The standard adult dose of DELTALIN is: 0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIJEX and DELTALIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIJEX is classified as Category C. Calcitriol (CALCIJEX) is a Vitamin D analog. Based on animal studies, there is evidence of teratogenicity at high doses (skeletal abnormalities, reduced fetal weight). Human data a. DELTALIN is classified as Category C. FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is hig. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.